Our research goal is to create innovative chemical tools, agents, and approaches for improving current targeted therapies for cancers and infectious diseases, including antibody-drug conjugates (ADCs). You can read on to find out more about these projects here.
June 28, 2023
The lab was awarded NIH/NCI R01 award!
June 28, 2022
Our paper on a novel cleavable ADC linker was accepted for publication in Molecular Cancer Therapeutics!
April 28, 2022
Our paper on the impact of ADC homogeneity on brain tumor targeting was accepted for publication in Cell Reports!
December 27, 2021
Our paper on antibody-angiopep 2 conjugates for brain targeting was accepted for publication in RSC Advances!
October 12, 2021
Kyoji received Outstanding Academic Investigator Award (8th World ADC Awards, 12th Annual World ADC San Diego)!
September 1, 2021
Kyoji was promoted to Tenured Associate Professor!
May 14, 2021
Our paper on dual-drug ADCs was accepted for publication in Nature Communications!
Featured in Nature Communications Editors' Highlight!!
January 4, 2021
Our paper on chemically constructed bispecific ADCs was accepted for publication in Bioorganic & Medicinal Chemistry!
December 21, 2020
Our preprint on dual-drug ADCs was posted on bioRxiv!
September 4, 2020
The lab was awarded NIH/NIGMS R35 MIRA award!
August 25, 2020
Our paper on ADCs for acute myeloid leukemia (AML) was accepted for publication in Molecular Cancer Therapeutics!
July 31, 2020
Dr. Yin Yuen Ha (Summer) joined our Lab!